MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day MIRM SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
5/8/2024
04:02 pm
mirm
mirum pharmaceuticals, inc. - common stock
MISS
3.2%
11/2/2023
04:05 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
5.7%
8/3/2023
04:05 pm
mirm
mirum pharmaceuticals, inc. - common stock
MISS
6.3%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
12/13 Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast 111.0%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
Top News Decliners
3/17 Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha] -10.7%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
MIRM
SPY
QQQ
SPX
MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
MIRM SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
5/10
07:30 pm
mirm
Low
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/10
01:39 pm
mirm
Low
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at Morgan Stanley from $57.00 to $53.00. They now have an "overweight" rating on the stock.
5/9
03:40 pm
mirm
Low
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target lowered by analysts at JMP Securities from $72.00 to $66.00. They now have a "market outperform" rating on the stock.
5/9
02:05 pm
mirm
Low
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $37.00 to $38.00. They now have a "buy" rating on the stock.
5/9
01:47 pm
mirm
Low
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
5/9
11:09 am
mirm
Low
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock.
5/9
08:17 am
mirm
Medium
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
5/8
04:02 pm
mirm
Medium
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
5/7
04:10 pm
mirm
Medium
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
5/8/2024
04:02 pm
mirm
3.2%
MISS
11/2/2023
04:05 pm
mirm
5.7%
BEAT
8/3/2023
04:05 pm
mirm
6.3%
MISS
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
5/10
11:42 am
Maintains
Overweight
Overweight
Morgan Stanley
Low
-2.9%
5/10
11:42 am
Maintains
Overweight
Overweight
Morgan Stanley
Low
-2.9%
5/9
02:37 pm
Maintains
Market Outperform
Market Outperform
JMP Securities
Low
0.1%
5/9
02:37 pm
Maintains
Market Outperform
Market Outperform
JMP Securities
Low
0.1%
5/9
01:42 pm
Maintains
Buy
Buy
Citigroup
Low
-1.9%
5/9
01:42 pm
Maintains
Buy
Buy
Citigroup
Low
-1.9%
5/9
11:09 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
-2.1%
5/9
10:24 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
-1.7%
5/9
08:17 am
Reiterates
Buy
Buy
HC Wainwright
Medium
3.5%
5/16
04:31 pm
mirm
Medium
Form 4 Mirum Pharmaceuticals, For: May 10 Filed by: Vig Pamela
5/16
04:31 pm
mirm
Medium
Form 4 Mirum Pharmaceuticals, For: May 10 Filed by: Peetz Christopher
5/16
04:31 pm
mirm
Medium
Form 4 Mirum Pharmaceuticals, For: May 10 Filed by: BJERKHOLT ERIC
5/8
04:17 pm
mirm
Medium
Form 10-Q Mirum Pharmaceuticals, For: Mar 31
5/8
04:05 pm
mirm
Medium
Form 8-K Mirum Pharmaceuticals, For: May 08
4/23
04:31 pm
mirm
Low
Form ARS Mirum Pharmaceuticals, For: Dec 31
4/23
04:22 pm
mirm
Low
Form DEFA14A Mirum Pharmaceuticals,
4/23
04:20 pm
mirm
Low
Form DEF 14A Mirum Pharmaceuticals, For: Apr 23
3/27
08:48 pm
mirm
Neutral
Form 4 Mirum Pharmaceuticals, For: Mar 27 Filed by: BJERKHOLT ERIC
Show more
Top News Gainers
12/13 Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast 111.0%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
Top News Decliners
3/17 Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha] -10.7%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%